Autolus Therapeutics plc

AUTL Nasdaq SEC CIK 1730463
Follow Autolus Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $41.2M +94.6% vs same quarter last year
Net income −$55.1M +30.4% vs same quarter last year
EPS, diluted −$0.21 +30% vs same quarter last year
Operating cash flow −$18.5M +72.7% vs same quarter last year
Revenue by quarter
$29K
$9M
$20.9M
$21.2M
$24.3M
$26.2M
$45.7M
$41.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$300M−$200M−$100M$0$100MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$75.4M−$287.5M
FY24$10.1M−$220.7M
FY23$1.7M−$208.4M
FY22-−$148.8M
FY21-−$142.1M
FY20-−$142.1M
FY19$2.9M−$123.8M
FY18$1.4M−$44.8M
FY17$1.7M−$19.7M
FY16$1.2M−$12.6M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−15000%−10000%−5000%0%5000%FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25−27.8%−358.9%−381.4%
FY24−12.5%−2385.6%−2180.5%
FY23100%−10583.1%−12272.3%
FY22---
FY21---
FY20---
FY19-−5022.8%−4258.9%
FY18-−4089.1%−3180.6%
FY17-−1383.2%−1165.2%
FY16--−1035.5%
Free cash flowOperating cash flow minus capital expenditure
−$400M−$300M−$200M−$100M$0FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$302.6M
FY24−$228.3M
FY23−$156.6M
FY22−$123.1M
FY21−$126.7M
FY20−$132.4M
FY19−$119.8M
FY18−$40.7M
FY17−$19.2M
FY16−$11.7M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Autolus Therapeutics
  • Healthcare median
−15000%−10000%−5000%0%FY17FY19FY21FY23FY25
Show the numbers
YearAutolus TherapeuticsHealthcare median
FY25−381.4%−30.6%
FY24−2180.5%−47%
FY23−12272.3%−58%
FY22-−80.4%
FY21-−71.9%
FY20-−62.2%
FY19−4258.9%−46.3%
FY18−3180.6%−49.6%
FY17−1165.2%−45.9%
FY16−1035.5%−36%